VJ/OA Journal Club: Dr. Misty Shields with the TOP Advances in Small Cell Lung Cancer
Dr. Misty Shields guides us through this great paper out on Cancer (ACS) on the TOP advances in Small Cell Lung Cancer. Small cell lung cancer (SCLC) remains a leading cause of cancer mortality, with its aggressive nature and frequent relapse leading to poor outcomes. In recent years, immunotherapy has provided some survival benefits, and in 2024, key breakthroughs have significantly improved patient outcomes. Notable advances include the use of consolidative durvalumab immunotherapy for limited-stage SCLC, new insights into timing immunotherapy with radiation, and promising treatments such as the bispecific T-cell engager tarlatamab and antibody-drug conjugates. Precision medicine approaches, like neuroendocrine subtyping, may guide future treatments, while advocacy efforts, such as the Small Cell SMASHERS group @SCLCSMASHERS , offer new support for patients with this historically stigmatized disease.Misty Dawn Shields MD PhD (Presenter and first author) Department of Medicine, Division of Hematology/Oncology, Indiana University School of Medicine, Indiana University Simon Comprehensive Cancer Center, Indianapolis, Indiana, USA
--------
4:38
Dr. Maryam Lustberg & Dr. Elisa Agostinetto discuss CDK4/6 inh in Breast cancer
Oncology Here & NowIn this interview, Dr. Elisa Agostinetto from the Jules Bordet Institute in Belgium speaks with Dr. Maryam Lustberg from Yale Cancer Center. Together, they dive deep into the use of CDK 4/6 inhibitors in the adjuvant treatment of breast cancer. Their discussion covers the use of Abemaciclib and Ribociclib following the monarchE and NATALEE trials, applications in the treatment of male breast cancer, and much more.Join us!
--------
15:33
Drs. Silke Gillessen & Aurelius Omlin of APCCC discuss Prostate Cancer, Hot Topics, APCCC & The Need for Consensus meetings
In this interview with Dr. Silke Gillessen & Dr. Aurelius Omlin , we delve into the origins, Topics and evolution of the Advanced #ProstateCancer Consensus Conference@APCCC_Lugano began in 2015 to address critical questions in prostate cancer management where evidence is lacking or conflicting. Over the years, the conference has focused on various evolving topics, such as oligometastatic disease, treatment sequencing, and new imaging technologies. The 2024 APCCC highlighted major discussions on next-generation imaging, genomic biomarkers, and diagnostic challenges, with a strong emphasis on the need to balance cutting-edge technology with clinical practicality. Looking ahead to APCCC 2026, the event will continue to address key issues, including the risk of overtreatment, international disparities in imaging access, and the integration of comorbidities into treatment decision-making. With a welcoming atmosphere, APCCC invites healthcare professionals worldwide to engage in these important discussions and contribute to shaping the future of prostate cancer care.
Brasil